アレルギー性鼻結膜炎(Allergic Rhino-Conjunctivitis):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Allergic Rhino-Conjunctivitis - Pipeline Review, H2 2014
◆商品コード:GMDHC5801IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:86
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるアレルギー性鼻結膜炎(Allergic Rhino-Conjunctivitis)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・アレルギー性鼻結膜炎(Allergic Rhino-Conjunctivitis)の概要
・アレルギー性鼻結膜炎(Allergic Rhino-Conjunctivitis)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・アレルギー性鼻結膜炎(Allergic Rhino-Conjunctivitis)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・アレルギー性鼻結膜炎(Allergic Rhino-Conjunctivitis)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・アレルギー性鼻結膜炎(Allergic Rhino-Conjunctivitis)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Allergic Rhino-Conjunctivitis – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Allergic Rhino-Conjunctivitis – Pipeline Review, H2 2014’, provides an overview of the Allergic Rhino-Conjunctivitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Allergic Rhino-Conjunctivitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Allergic Rhino-Conjunctivitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Allergic Rhino-Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Allergic Rhino-Conjunctivitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Allergic Rhino-Conjunctivitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Allergic Rhino-Conjunctivitis Overview 8
Therapeutics Development 9
Pipeline Products for Allergic Rhino-Conjunctivitis – Overview 9
Pipeline Products for Allergic Rhino-Conjunctivitis – Comparative Analysis 10
Allergic Rhino-Conjunctivitis – Therapeutics under Development by Companies 11
Allergic Rhino-Conjunctivitis – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Allergic Rhino-Conjunctivitis – Products under Development by Companies 15
Allergic Rhino-Conjunctivitis – Companies Involved in Therapeutics Development 17
ALK-Abello A/S 17
Allergopharma Joachim Ganzer KG 18
Allergy Therapeutics plc 19
Anergis SA 20
Bial – Portela & Ca, S.A. 21
BioTech Tools s.a. 22
Circassia Pharmaceuticals plc 23
Greer Laboratories, Inc. 24
HAL Allergy BV 25
Immunomic Therapeutics, Inc. 26
Laboratorios LETI S.L. 27
Stallergenes S.A. 28
Allergic Rhino-Conjunctivitis – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
Acaroid – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AL-0704rP – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ALK Birch Pollen Vaccine – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Allergovac – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AllerT – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Avanz Cupressus Immunotherapy for Allergic Rhino-Conjunctivitis – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Avanz Phleum Pratense – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Avanz Salsola Immunotherapy for Allergic Rhino-Conjunctivitis – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Depigoid Birch – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Dermatophagoides Pteronyssinus Allergen Extract – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
gpASIT + TM – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Grass Pollen Allergoid – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Grass-SPIRE – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
House Dust Mite-SPIRE – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
JRC-LAMP-Vax – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MK-8237 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Olea Europaea Pollen Extract – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Pollinex Quattro Grass – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Ragweed Pollen Extract – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
rBet v1 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
rBet v1-FV – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
rPhleum – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Allergic Rhino-Conjunctivitis – Recent Pipeline Updates 69
Allergic Rhino-Conjunctivitis – Dormant Projects 77
Allergic Rhino-Conjunctivitis – Discontinued Products 78
Allergic Rhino-Conjunctivitis – Product Development Milestones 79
Featured News & Press Releases 79
Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen 79
May 18, 2014: BioTech Tools will be present at the EAACI congress 80
Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology 81
Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics 82
Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites 83
Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA 83
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 86
Disclaimer 86

[List of Tables]
Number of Products under Development for Allergic Rhino-Conjunctivitis, H2 2014 9
Number of Products under Development for Allergic Rhino-Conjunctivitis - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Development by Companies, H2 2014 (Contd..1) 16
Allergic Rhino-Conjunctivitis - Pipeline by ALK-Abello A/S, H2 2014 17
Allergic Rhino-Conjunctivitis - Pipeline by Allergopharma Joachim Ganzer KG, H2 2014 18
Allergic Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics plc, H2 2014 19
Allergic Rhino-Conjunctivitis - Pipeline by Anergis SA, H2 2014 20
Allergic Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca, S.A., H2 2014 21
Allergic Rhino-Conjunctivitis - Pipeline by BioTech Tools s.a., H2 2014 22
Allergic Rhino-Conjunctivitis - Pipeline by Circassia Pharmaceuticals plc, H2 2014 23
Allergic Rhino-Conjunctivitis - Pipeline by Greer Laboratories, Inc., H2 2014 24
Allergic Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H2 2014 25
Allergic Rhino-Conjunctivitis - Pipeline by Immunomic Therapeutics, Inc., H2 2014 26
Allergic Rhino-Conjunctivitis - Pipeline by Laboratorios LETI S.L., H2 2014 27
Allergic Rhino-Conjunctivitis - Pipeline by Stallergenes S.A., H2 2014 28
Assessment by Monotherapy Products, H2 2014 29
Assessment by Combination Products, H2 2014 30
Number of Products by Stage and Target, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 35
Allergic Rhino-Conjunctivitis Therapeutics - Recent Pipeline Updates, H2 2014 69
Allergic Rhino-Conjunctivitis - Dormant Projects, H2 2014 77
Allergic Rhino-Conjunctivitis - Discontinued Products, H2 2014 78

[List of Figures]
Number of Products under Development for Allergic Rhino-Conjunctivitis, H2 2014 9
Number of Products under Development for Allergic Rhino-Conjunctivitis - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Assessment by Monotherapy Products, H2 2014 29
Number of Products by Top 10 Routes of Administration, H2 2014 32
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 33
Number of Products by Top 10 Molecule Types, H2 2014 34
Number of Products by Stage and Top 10 Molecule Types, H2 2014 35

【掲載企業】

ALK-Abello A/S
Allergopharma Joachim Ganzer KG
Allergy Therapeutics plc
Anergis SA
Bial - Portela & Ca, S.A.
BioTech Tools s.a.
Circassia Pharmaceuticals plc
Greer Laboratories, Inc.
HAL Allergy BV
Immunomic Therapeutics, Inc.
Laboratorios LETI S.L.
Stallergenes S.A.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アレルギー性鼻結膜炎(Allergic Rhino-Conjunctivitis):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆